le sage des temps modernes

Cuisinier passionné,adorateur du savoir, partageur de bonheur.

[le sage des temps modernes @SimonBabajko]

@YunaBNB 80000, 40 to clear Dept and 40 to put in reer , but 40000 is the minimum to change everything

[le sage des temps modernes @SimonBabajko]

@pumpsxsol Yes

[le sage des temps modernes @SimonBabajko]

@princexsol 80000$

[le sage des temps modernes @SimonBabajko]

@stan_niesman 40k to clear all mine and the university of my girlfriend. Alone, 20k

[le sage des temps modernes @SimonBabajko]

@stan_niesman 80K, 40k for debts (university) 20k to our in a reer and 20k to invest in AIM immunotech. A speculative biotech but analysis predicted a grown of 3000% actually, my 3k for aim, if it reaches 7$ get to 100k

[Daily NTE @NTEDaily]

Dragon Maid!

#NevernessToEverness

[le sage des temps modernes @SimonBabajko]

@princexsol [email protected]

[le sage des temps modernes @SimonBabajko]

@princexsol @MrketInsider Hey

[le sage des temps modernes @SimonBabajko]

@princexsol 2600 to invest in AIM immunotech, for oncology

[AIM ImmunoTech @AimImmuno]

$AIM ImmunoTech announced the publication of a new Breaking Defense article by CEO Thomas K. Equels highlighting biodefense, military force protection and the potential role of Ampligen® as a broad-spectrum antiviral countermeasure.

Read more: https://t.co/TcaeBYz6LX

[AIM ImmunoTech @AimImmuno]

Advancing biodefense requires a proactive approach to identifying emerging threats and developing countermeasures that can help protect those who serve.

At $AIM, we recognize the importance of preparedness in supporting military force protection and readiness.

#Oncology

[le sage des temps modernes @SimonBabajko]

@princexsol 1500 to invest in AIM immunotech. A biotech who try to figure how to heal pancreatic cancer

[AIM ImmunoTech @AimImmuno]

The need for better pancreatic cancer treatments has never been greater.

Today, the overall 5-year survival rate remains just 13%, highlighting the importance of continued innovation in this disease.

$AIM #Oncology #PancreaticCancer #CancerResearch

[le sage des temps modernes @SimonBabajko]

@Nteupdates I Will pull for zankou

[AIM ImmunoTech @AimImmuno]

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

https://t.co/TcaeBYz6LX
$AIM #PancreaticCancer #Oncology #CancerResearch

[AIM ImmunoTech @AimImmuno]

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer

https://t.co/iKd8c74BCn
$AIM #PancreaticCancer #Oncology #CancerResearch

[AIM ImmunoTech @AimImmuno]

Stay informed with AIM ImmunoTech.

Sign up to receive our latest press releases, SEC filings, investor updates and other company news delivered directly to your inbox.

Register here: https://t.co/KAuMlUPjop

$AIM #Oncology #CancerResearch #Immunology

[AIM ImmunoTech @AimImmuno]

New coverage from @MedWorldNews highlights $AIMs ongoing work advancing Ampligen® in pancreatic cancer.

Read more about the Phase 2 DURIPANC trial and our efforts to address a significant unmet need: https://t.co/YDVROTjnYx

#CancerResearch